Publication date: Aug 04, 2026
According to a study published in The Journal of Immunology, researchers investigated T cell responses following COVID-19 vaccination in individuals with inflammatory bowel disease (IBD) treated with anti-TNF or anti-IL-12/23 biologics. Initial analysis revealed that IBD patients, regardless of treatment status, exhibited reduced Spike-specific IL-2 production and Th1 polarization compared to healthy controls after the first vaccine dose. However, after two or three doses, T cell subsets and responses became largely indistinguishable between treated IBD patients and healthy controls. These findings suggest that anti-cytokine biologics do not significantly impair long-term vaccine-induced memory T cell responses in IBD patients following multiple COVID-19 vaccine doses.
| Concepts | Keywords |
|---|---|
| Immunologists | Anti |
| Mrna | Biologics |
| Professor | Controls |
| Toronto | Covid |
| Waning | Cytokine |
| Dr | |
| Healthy | |
| Ibd | |
| Il | |
| Immunology | |
| Specific | |
| Spike | |
| Treated | |
| Vaccine | |
| Vaccines |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | psoriatic arthritis |
| disease | MESH | ankylosing spondylitis |
| pathway | KEGG | Rheumatoid arthritis |
| disease | MESH | rheumatoid arthritis |